In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
Ikenna Madueke, MD, PhD
Advertisement
Articles by Ikenna Madueke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
AI and MRD Take Center Stage on Day 2 of ASCO Breakthrough 2026
2
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
3
Cellular Therapy and Antibody-Drug Conjugates Shape Day 1 of ASCO Breakthrough 2026
4
GLP-1 Receptor Agonists Reduce Colorectal Cancer Risk in IBD Populations
5